Provider delay in treatment initiation and its influence on survival outcomes in women with operable breast cancer.

Flores-Balcázar, Christian H; Flores-Luna, Ma L; Villarreal-Garza, Cynthia M; Bargalló-Rocha, Juan E

Flores-Balcázar, Christian H; Flores-Luna, Ma L; Villarreal-Garza, Cynthia M; Bargalló-Rocha, Juan E.

Afiliação

Flores-Balcázar CH; Department of Radiation-Oncology, National Cancer Institute, 22 San Fernando Ave, Section XVI, Tlalpan, Mexico City 14080, Mexico.
Flores-Luna ML; Department of Epidemiology, National Institute of Public Health, 50 Fray Pedro de Gante, Section XVI, Tlalpan, Mexico City 14080, Mexico.
Villarreal-Garza CM; Department of Breast Tumors, National Cancer Institute, 22 San Fernando Ave, Section XVI, Tlalpan, Mexico City 14080, Mexico.
Bargalló-Rocha JE; Department of Breast Tumors, National Cancer Institute, 22 San Fernando Ave, Section XVI, Tlalpan, Mexico City 14080, Mexico.

Rep Pract Oncol Radiother ; 25(2): 271-275, 2020.

Article em En | MEDLINE | ID: mdl-32140085

Palavras-chave

BrCa, breast cancer; Breast cancer chemotherapy; Breast cancer radiotherapy; Breast cancer surgery; CSS, cancer-specific survival; ER, estrogen receptor; HR, hazard ratio; IQR, interquartile range; OR, odds ratio; Timing of cancer treatment; Treatment delay

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Tipo de estudo: Prognostic_studies Idioma: En Revista: Rep Pract Oncol Radiother Ano de publicação: 2020 Tipo de documento: Article País de afiliação: México

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google